99% Savings - Buy Just @1 Rs X
Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet, a prescription drug, is manufactured in various forms such as Tablet. Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet also has some secondary and off-label uses. These are listed below.
The optimal dosage of Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet is largely dependent on the individual's body weight, medical history, gender and age. Dosage also depends on the route of administration and your chief complaint for which the drug is prescribed. For detailed information on this, read through the dosage section.
The most common side effects of Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet are Rash, Flatulence, Diarrhoea. Apart from the aforementioned side effects, Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet can also lead to other problems, which have been listed below. Normally, these side effects of Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet are not long lasting and go away when the treatment is finished. Please speak with your doctor if these side effects worsen or persist for a longer duration.
Furthermore, you should know that effect of Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet is Severe for pregnant women and Severe for women who are breastfeeding. It is important to know if Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet has any effect on the kidney, liver and heart. Information on such adverse effects, if any, has been given in the Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet related warnings section.
Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet is contraindicated in people with pre-existing medical conditions like Digestive Disorders, Intestinal Obstruction, Allergy as it can result in adverse effects. Other conditions have been mentioned below in the Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet contraindications section.
Besides this, Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet may also have severe interaction with some medicines. See below for a complete list.
Along with the above-mentioned precautions, remember that taking Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet is considered safe while driving, and is addictive.
Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
Is the use of Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet safe for pregnant women?
Gliclapack MV shows severe side effect on pregnant women. For this reason, pregnant women should only take it after taking medical advice.
Is the use of Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet safe during breastfeeding?
Gliclapack MV may cause serious side effects in breastfeeding women, so do not take this drug without doctor's advice.
What is the effect of Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet on the Kidneys?
There can be some harmful effects on your kidneys after taking Gliclapack MV. If you witness any side effects, discontinue its use. Consult your medical practitioner, do as he/she suggests.
What is the effect of Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet on the Liver?
The liver can be affected by Gliclapack MV. If you experience any unwanted effects of this drug, stop taking it and consult your doctor. You should restart Gliclapack MV only after medical advice.
What is the effect of Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet on the Heart?
Gliclapack MV may have mild side effects on the heart. Most people will never see any effect on the heart.
If you are suffering from any of the following diseases, you should not take Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet unless your doctor advises you to do so -
Is this Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet habit forming or addictive?
Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet does not cause addiction.
Interaction between Food and Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet
There is no information on the effects of taking Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet with food, because this topic has not been scientifically researched yet.
Interaction between Alcohol and Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet
Consult your doctor before consuming alcohol while taking Gliclapack MV 0.2 Mg/500 Mg/80 Mg Tablet as it can have severe side effects.
Gliclapack MV should be taken as long as needed or take it as directed by doctor. Do not discontinue the drug suddenly or take it longer than prescribed by your doctor.
Yes, Gliclapack MV is safe to use, if taken in prescribed amount and duration as advised by the doctor. However, certain side effects have been associated with this drug such as dizziness, nausea, and vomiting. If you experience any discomfort after taking this medicine then inform your doctor immediately and follow his/her instructions.
Yes, Gliclapack MV can cause some sleep problems. The exact cause of sleep problems is still not clear. It is best to consult your doctor if you experience sleepiness after consuming medicine.
Gliclapack MV contain voglibose. It works by inhibiting the enzyme (alpha-glucosidase) that reduces the rate of digestion of complex carbohydrates. Less glucose is absorbed because the carbohydrates are not broken down into glucose molecules. Hence in this way, Gliclapack MV reduces blood sugar levels.
Gliclapack MV is the brand name for voglibose. It is an oral antidiabetic drug that belongs to the class of medicine called alpha-glucosidase inhibitor. It is used in single or combined with other drugs to treat diabetes.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 277
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Glucophage® (metformin hydrochloride)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 275-276
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 825-826
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 272
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1314-1315